Surgery corticosteroids

As a protective mechanism, the corticosteroids are released during periods of stress (eg, injury or surgery). The release of epinephrine or norepinephrine by the adrenal medulla during stress has a synergistic effect along with the corticosteroids. 

Glucosamine, tramadol, opioids, topical capsaicin, intraartic-ular corticosteroids, and surgery may be beneficial in certain situations. 

For patients receiving corticosteroids, monitor for adverse effects and drug interactions. Does the patient need GI prophylaxis for long-term treatment Slowly taper once symptoms improve and/or radiation or surgery is completed. 

Wound healing Because of the inhibitory effect of corticosteroids on wound healing in patients who have experienced recent nasal septal ulcers, recurrent epistaxis, nasal surgery, or trauma, use nasal steroids with caution until healing has occurred. Vasoconstrictors In the presence of excessive nasal mucosa secretion or edema of the nasal mucosa, the drug may fail to reach the site of intended action. In such cases, use a nasal vasoconstrictor during the first 2 to 3 days of therapy. 

After the surgery, new antibodies and killer lymphocytes that cause rejection may develop within days. To prevent this from happening, or at least reduce the chances of it, scientists have discovered and developed a number of immunosuppressive drugs that help extend the life of the transplanted organ and, thus, the life of its recipient. Corticosteroids and the cancer chemotherapy drug azathioprine were the first drugs used to suppress the immune system for organ... 

Treatments are broadly the same as for ulcerative colitis being based on appropriate supportive measures, and the use of corticosteroids, the cytokine infliximab or adalimumab for severe and complicated disease and immunosuppressants, typically azathio-prine, for reducing the chances of relapse. Full thickness disease leading to flstulation, free perforation, abscess formation and stricturing usually requires surgery. Aminosalicylates appear ineffective in reducing the chances of relapse. 

A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with concomitant risk factors (e.g., cancer, chemotherapy, corticosteroid use, poor oral hygiene). While on bis-phosphonate treatment, patients with concomitant risk factors should avoid invasive dental procedures if possible. For patients who develop osteonecrosis of the jaw while on bisphosphonate therapy, dental surgery may exacerbate the condition. For patients requiring dental procedures, there are no data available to suggest whether discontinuation of bisphosphonate treatment reduces the risk of osteonecrosis of the jaw. 

When corticosteroids are administered for more than 2 weeks, adrenal suppression may occur. If treatment extends over weeks to months, the patient should be given appropriate supplementary therapy at times of minor stress (two-fold dosage increases for 24-48 hours) or severe stress (up to ten-fold dosage increases for 48-72 hours) such as accidental trauma or major surgery. If corticosteroid dosage is to be reduced, it should be tapered slowly. If therapy is to be stopped, the reduction process should be quite slow when the dose reaches replacement levels. It may take 2-12 months for the hypothalamic-pituitary-adrenal axis to function acceptably, and cortisol levels may not return to normal for another 6-9 months. The glucocorticoid-induced suppression is not a pituitary problem, and treatment with ACTH does not reduce the time required for the return of normal function. 

Therapeutic pyramid approach to inflammatory bowel diseases. Treatment choice is predicated on both the severity of the illness and the responsiveness to therapy. Agents at the bottom of the pyramid are less efficacious but carry a lower risk of serious adverse effects. Drugs may be used alone or in various combinations. Patients with mild disease may be treated with 5-aminosalicylates (with ulcerative colitis or Crohn s colitis), topical corticosteroids (ulcerative colitis), antibiotics (Crohn s colitis or Crohn s perianal disease), or budesonide (Crohn s ileitis). Patients with moderate disease or patients who fail initial therapy for mild disease may be treated with oral corticosteroids to promote disease remission immunomodulators (azathioprine, mercaptopurine, methotrexate) to promote or maintain disease remission or anti-TNF antibodies. Patients with moderate disease who fail other therapies or patients with severe disease may require intravenous corticosteroids, anti-TNF antibodies, or surgery. Natalizumab is reserved for patients with severe Crohn s disease who have failed immunomodulators and TNF antagonists. Cyclosporine is used primarily for patients with severe ulcerative colitis who have failed a course of intravenous corticosteroids. TNF, tumor necrosis factor. 

Grabner W. Zur induzierten NNR-Insuffizienz bei chirur-gischen Eingriffen. [Problems of corticosteroid-induced adrenal insufficiency in surgery.] Fortschr Med 1977 95(30) 1866-8. 

---